DOI: 10.1128/CVI.00071-16
Article Information
PubMed
Published By
History
- Received February 12, 2016
- Returned for modification February 29, 2016
- Accepted June 22, 2016
- Published online September 6, 2016.
Copyright & Usage
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Editors and / or Reviewers
- R. S. Abraham, Editor, Mayo Clinic
Article Versions
- Accepted Manuscript version (June 29, 2016).
- You are viewing the most recent version of this article.
Author Information
- John N. Aucotta,
- Mark J. Soloskia,
- Alison W. Rebmana,
- Lauren A. Crowderb*,
- Lauren J. Laheyc*,
- Catriona A. Wagnerc*,
- William H. Robinsonc and
- Kathleen T. Bechtoldd
- aDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Lutherville, Maryland, USA
- bLyme Disease Research Foundation, Lutherville, Maryland, USA
- cDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA, and Veterans Affairs Palo Alto Health Care System CCSR, Palo Alto, California, USA
- dDepartment of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Address correspondence to John N. Aucott, jaucott2{at}jhmi.edu.
↵* Present address: Lauren A. Crowder, American Red Cross, Rockville, Maryland, USA; Lauren J. Lahey, Biophysics Graduate Program, Stanford University School of Medicine, Stanford, California, USA; Catriona A. Wagner, Immunology Graduate Program, University of Washington Department of Immunology, Seattle, Washington, USA.
Citation Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Bechtold KT. 2016. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol 23:757–766. doi:10.1128/CVI.00071-16.
Article usage
CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study
